Your session is about to expire
← Back to Search
Acupuncture for Urinary Issues in Prostate Cancer Survivors
Phase 1 & 2
Waitlist Available
Led By Kevin Liou, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group
Summary
This trial will study whether acupuncture can help reduce nocturia in prostate cancer survivors.
Who is the study for?
This trial is for prostate cancer survivors over 18 with no current evidence of cancer, experiencing frequent nighttime urination (nocturia). They must not have started new urinary medications or changed doses in the last month and can't have untreated sleep disorders, psychiatric conditions, or be at high risk for obstructive sleep apnea.
What is being tested?
The study tests if acupuncture can help reduce nocturia in prostate cancer survivors. It's a first-of-its-kind study to see if this traditional technique could also ease insomnia, hot flashes, anxiety, depression, fatigue, sexual dysfunction and cognitive issues related to prostate cancer survivorship.
What are the potential side effects?
Acupuncture may cause minor side effects such as soreness or bruising at needle sites. More serious side effects are rare but can include infections or injury from needles.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
success
Side effects data
From 2013 Phase 1 & 2 trial • 104 Patients • NCT013058112%
Serious unexpected
2%
Pain on needling
100%
80%
60%
40%
20%
0%
Study treatment Arm
Bi-Weekly Acupuncture
Wait List
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Waitlist ControlExperimental Treatment2 Interventions
The waitlist control group will not receive any acupuncture treatments during the 14-week waiting period. Patients in waitlist control group will have the option to receive up to 10 acupuncture treatments after a 14-week waiting period.
Group II: AcupunctureExperimental Treatment2 Interventions
Acupuncture group will receive 10 treatments of acupuncture over the course of 10 weeks (i.e. one treatment a week) with a +/- 14-day window.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Acupuncture
2011
Completed Phase 3
~1240
Find a Location
Who is running the clinical trial?
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,979 Previous Clinical Trials
600,018 Total Patients Enrolled
Kevin Liou, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have changed my medication for urinary problems in the last month.I have been diagnosed with prostate cancer before.I do not have prostate cancer.I plan to start or change treatments for urinary symptoms during the study.I am unable to give consent by myself.I wake up to urinate 2 or more times every night for the last month.I have an untreated sleep disorder that is not insomnia.I finished my prostate cancer treatment less than a month ago.I started new medication for urinary problems less than a month ago.I am 18 years old or older.
Research Study Groups:
This trial has the following groups:- Group 1: Acupuncture
- Group 2: Waitlist Control
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.